ReviewMolecular biotechnology2026
Research Advances in Multi-tissue Organoid Models Based on PBMCs.
Review in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Patient-Derived Organoids in Gastrointestinal Disease: Current Applications, Limitations, and Future Perspectives.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organoids, as three-dimensional in vitro culture models, closely recapitulate the architectural, cellular, and functional characteristics of their in vivo counterparts. Consequently, they play a pivotal role in diverse biomedical fields, including disease modeling, drug screening, and regenerative medicine. However, conventional organoid models often lack a complex native microenvironment, specifically the tumor microenvironment (TME), which limits their utility in studying immune-related pathologies and evaluating immunotherapeutic strategies. Peripheral blood mononuclear cells (PBMCs) offer distinct advantages, including accessibility, a heterogeneous composition of immune cells, and the capacity to mirror a patient's specific immune status. As a result, PBMCs have emerged as a predominant source of immune cells for engineering immune-integrated organoid models. This article reviews recent advancements in integrating PBMCs into various tissue organoid systems. It summarizes the key biological properties of PBMCs and their applications across multiple models, including cerebral, renal, pulmonary, and hepatic organoids. Furthermore, this study compares the advantages and limitations of current modeling methodologies and discusses future research directions and persistent challenges in leveraging PBMC-integrated organoids for personalized medicine and the elucidation of disease mechanisms.
Indexed as
Identifiers
42029803What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.